Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

Jhanelle E. Gray,Taofeek K. Owonikoko,Terufumi Kato,Andres Felipe Cardona Zorrilla,Joanne Wagman,X. Chen,Bin Zhao,Christian Schulz

Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

2020

Jhanelle E. Gray
Taofeek K. Owonikoko
Terufumi Kato
Andres Felipe Cardona Zorrilla
Joanne Wagman
X. Chen
Bin Zhao
Christian Schulz

TPS9632Background: First-line treatment with pembrolizumab + pemetrexed/platinum improved clinical outcomes in patients with advanced nonsquamous NSCLC in KEYNOTE-021 and KEYNOTE-189. Poly(ADP-ribo...

Keywords:

Pemetrexed
Oncology
Olaparib
Internal medicine
in patient
Pembrolizumab
first line
Pathology
non-small cell lung cancer (NSCLC)
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations